Markets:

Overview

News

Currencies

International

Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

1.100 -0.010 (-0.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

March 27, 2025

Via ACCESS Newswire

Which stocks are gapping on Thursday? ↗

March 27, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results ↗

March 27, 2025

Via Benzinga

Dermata to Present on BioPub on January 31, 2025

January 29, 2025

Via ACCESS Newswire

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

December 16, 2024

Via ACCESSWIRE

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

December 10, 2024

Via ACCESSWIRE

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 03, 2024

Via ACCESSWIRE

Top movers in Thursday's pre-market session ↗

March 27, 2025

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne ↗

March 27, 2025

Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025.

Via Benzinga

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall ↗

March 27, 2025

Via Benzinga

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

March 17, 2025

Via ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 13, 2024

Via ACCESSWIRE

Peering Into Dermata Therapeutics's Recent Short Interest ↗

August 07, 2024

Via Benzinga

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 07, 2024

Via ACCESSWIRE

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

February 25, 2025

Via ACCESS Newswire

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

January 22, 2025

Via ACCESS Newswire

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

January 21, 2025

Via ACCESS Newswire

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

November 15, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Life Sciences Investor Forum Agenda Announced for November 14th

November 12, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

November 11, 2024

– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –

From Virtual Investor Conferences

Via GlobeNewswire

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

October 08, 2024

Via ACCESSWIRE

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

September 17, 2024

Via ACCESSWIRE

Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗

September 17, 2024

Via Benzinga

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

September 16, 2024

Via ACCESSWIRE

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September ↗

September 16, 2024

Via Benzinga

Topics Stocks

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗

September 16, 2024

Via Benzinga

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

September 05, 2024

Via ACCESSWIRE

Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

August 21, 2024

Via Benzinga

7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024 ↗

August 09, 2024

If your growth stocks have stopped growing then you may be holding on to F-rated growth stocks. It's time to sell.

Via InvestorPlace

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024 ↗

August 07, 2024

DRMA stock results show that Dermata Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.